You are here
Visiongain Report Offers Transformative Insights on the $8.6bn Inflammatory Bowel Diseases (IBD) Drug Market
LONDON, Aug. 30, 2019 /PRNewswire/ -- The global inflammatory bowel diseases (IBD) drug market is estimated at $7.2bn in 2018. Biologic therapies held 65% share of the IBD market in 2018 and is estimated to grow at a CAGR of 3.6% in the first half of the forecast period.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 245-page report you will receive 119 tables and 77 figures– all unavailable elsewhere.
The 245-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.
By ordering and reading Visiongain's brand-new report today you stay better informed and ready to act.
To request sample pages from this report please contact Sara Peerun at email@example.com or refer to our website: https://www.visiongain.com/report/global-inflammatory-bowel-diseases-ibd-drug-market-forecast-2019-2029/#download_sampe_div
• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2019-2029
• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2019-2029 by Indication:
• Crohn's Disease
• Ulcerative Colitis
• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2019-2029 by Distribution Channel:
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2019-2029 by Drug Class:
• Revenue forecast from 2019-2029 for the selected leading products:
• Revenue forecasts from 2019-2029 for these national markets segmented by indication, drug class and distribution channel:
• Germany, France, UK, Spain and Italy (EU5)
• Brazil, Russia, India and China (BRIC)
• Discussions on research and development, including drug candidates in these classes:
• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF-alpha inhibitors
• Stem cell therapies
• JAK inhibitors
• Toll-like receptor agonists
• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry:
• Celgene Corporation
• Gilead Sciences
• UCB Pharma S.A.
• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the IBD market. Moreover, this report discusses factors that drive and restrain the IBD market.
• Key questions answered by this report:
• How is the inflammatory bowel disease drugs industry and market evolving?
• What is the technological and commercial potential of those IBD therapies from 2019?
• What sales values are possible at overall world, submarket, product and national levels?
• What are the market shares of its segments and how will they change to 2029?
• How much will those submarkets' revenues expand from 2019 to 2029?
• Which medicines will dominate and how high can leading brands' revenues go from 2019 to 2029? Which products will gain in sales and which will lose market shares?
• What forces stimulate and restrain that industry and market from 2019 to 2029?
• How will political and economic issues affect that overall sector and its submarkets?
• How will relative shares of national markets change by 2029, and which region will lead the world then? How high will leading national revenues go?
• Who form the leading companies, what do they offer, and what are their commercial prospects?
To request a report overview of this report please contact Sara Peerun at firstname.lastname@example.org or refer to our website: https://www.visiongain.com/report/global-inflammatory-bowel-diseases-ibd-drug-market-forecast-2019-2029/
Did you know that we also offer a report add-on service? Email email@example.com to discuss any customized research needs you may have.
Companies covered in the report include:
Centocor Ortho Biotech
Dr. Falk Pharma
Johnson & Johnson
Kissei Pharmaceutical Co., Ltd
Reliance Life Sciences
Teva Pharmaceutical Industries
Torrent Pharmaceuticals Ltd.
List of Organisations Mentioned in the Report
American Gastroenterological Association (AGA)
Case Western Reserve University
Center for Human Disease Research, Leiden
Centrale Commissie Mensgebonden Onderzoek (CCMO)
Centres for Disease Control and Prevention (US)
Crohn's and Colitis Foundation of Canada
European Crohn's and Colitis Organisation (ECCO)
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Georgia State University
German Society of Gastroenterology (DGVS)
Hebrew University of Jerusalem
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Institut National de la Santé et de la Recherche Médicale (INSERM)
National Health Service (UK NHS)
National Institute for Health and Care Excellence (UK NICE)
National Institutes of Health (US NIH)
Servicio Sanitario Nazionale (SSN, Italy)
The Crohn's and Colitis UK Foundation
The European Federation of Crohn's and Ulcerative Colitis Associations
The Scripps Research Institute (TSRI)
The University of Iowa
To see a report overview please e-mail Sara Peerun on firstname.lastname@example.org